Question 1

Q: Which of the following statements about ramelteon is false?

Has high addiction liability. ***Has high addiction liability*** - Ramelteon is a **melatonin receptor agonist** that does not bind to GABA receptors, distinguishing it from benzodiazepines and Z-drugs (zolpidem, eszopiclone, zaleplon). - Its mechanism of action leads to a **very low risk of abuse and dependence**, contrary to the statement. *Is a substrate of CYP1A2* - Ramelteon is extensively metabolized in the liver, primarily by **CYP1A2**, which is accurate. - This metabolic pathway can lead to drug interactions if co-administered with **CYP1A2 inhibitors** (e.g., fluvoxamine), which can significantly increase ramelteon concentrations. *Approved for treatment of insomnia* - Ramelteon is indeed indicated for the **treatment of insomnia**, particularly for difficulties with **sleep onset**. - It works by mimicking the action of **melatonin**, promoting the regulation of the sleep-wake cycle. *Agonist at MT1 and MT2 receptors* - Ramelteon acts as a **selective agonist** at the **melatonin MT1 and MT2 receptors** in the suprachiasmatic nucleus. - Activation of these receptors helps to modulate the **circadian rhythm**, thereby promoting sleep.

Question

Which of the following statements about ramelteon is false?

Accepted Answer

Has high addiction liability

Answer

Is a substrate of CYP1A2

Answer

Approved for treatment of insomnia

Answer

Agonist at MT1 and MT2 receptors

Central Nervous System Pharmacology — MCQs

Central Nervous System Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?